Cann Group Past Earnings Performance
Past criteria checks 0/6
Cann Group's earnings have been declining at an average annual rate of -23.8%, while the Pharmaceuticals industry saw earnings growing at 34.5% annually. Revenues have been growing at an average rate of 40.6% per year.
Key information
-23.8%
Earnings growth rate
1.9%
EPS growth rate
Pharmaceuticals Industry Growth | 31.2% |
Revenue growth rate | 40.6% |
Return on equity | -368.1% |
Net Margin | -268.6% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Cann Group Limited's (ASX:CAN) Low P/S No Reason For Excitement
Jun 04A Piece Of The Puzzle Missing From Cann Group Limited's (ASX:CAN) Share Price
Dec 27Cann Group (ASX:CAN) Is Making Moderate Use Of Debt
May 18Shareholders May Be A Bit More Conservative With Cann Group Limited's (ASX:CAN) CEO Compensation For Now
Nov 03Here's Why We're Not Too Worried About Cann Group's (ASX:CAN) Cash Burn Situation
Feb 23What Type Of Returns Would Cann Group's(ASX:CAN) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?
Nov 25One Forecaster Is Now More Bearish On Cann Group Limited (ASX:CAN) Than They Used To Be
Nov 25Revenue & Expenses Breakdown
How Cann Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 19 | -51 | 19 | 1 |
31 Mar 24 | 20 | -40 | 30 | 1 |
31 Dec 23 | 21 | -29 | 35 | 2 |
30 Sep 23 | 21 | -32 | 35 | 3 |
30 Jun 23 | 21 | -34 | 34 | 4 |
31 Mar 23 | 18 | -35 | 28 | 4 |
31 Dec 22 | 14 | -37 | 27 | 5 |
30 Sep 22 | 13 | -32 | 27 | 4 |
30 Jun 22 | 11 | -26 | 28 | 3 |
31 Mar 22 | 10 | -25 | 27 | 2 |
31 Dec 21 | 9 | -24 | 26 | 2 |
30 Sep 21 | 9 | -25 | 25 | 2 |
30 Jun 21 | 9 | -25 | 23 | 2 |
31 Mar 21 | 7 | -22 | 19 | 2 |
31 Dec 20 | 6 | -18 | 15 | 2 |
30 Sep 20 | 4 | -17 | 14 | 2 |
30 Jun 20 | 2 | -17 | 14 | 1 |
31 Mar 20 | 2 | -16 | 15 | 1 |
31 Dec 19 | 3 | -14 | 16 | 1 |
30 Sep 19 | 3 | -13 | 15 | 1 |
30 Jun 19 | 3 | -11 | 13 | 1 |
31 Mar 19 | 2 | -10 | 11 | 1 |
31 Dec 18 | 1 | -8 | 9 | 1 |
30 Sep 18 | 1 | -6 | 7 | 1 |
30 Jun 18 | 1 | -5 | 6 | 1 |
31 Mar 18 | 0 | -4 | 4 | 1 |
31 Dec 17 | 0 | -3 | 2 | 0 |
30 Sep 17 | 0 | -3 | 2 | 1 |
30 Jun 17 | 0 | -3 | 2 | 1 |
30 Jun 16 | 0 | -1 | 1 | 0 |
30 Jun 15 | 0 | -4 | 4 | 0 |
Quality Earnings: CAN is currently unprofitable.
Growing Profit Margin: CAN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CAN is unprofitable, and losses have increased over the past 5 years at a rate of 23.8% per year.
Accelerating Growth: Unable to compare CAN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CAN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (46.5%).
Return on Equity
High ROE: CAN has a negative Return on Equity (-368.09%), as it is currently unprofitable.